Preparation of Patchouli Oil Microemulsion Gel and Its Topical Application to Ameliorate Atopic Dermatitis in Mice

Patchouli oil (PO) is a natural substance famous for its immune-enhancing and anti-inflammatory effects. Atopic dermatitis (AD) is characterized by epidermal gene mutations, skin barrier dysfunction, and immune dysregulation, making patchouli volatile oil a potential candidate for AD treatment. Init...

Full description

Saved in:
Bibliographic Details
Published in:Gels 2024-12, Vol.10 (12), p.796
Main Authors: Chen, Tingting, Xu, Changjin, Wang, Min, Cui, Yan, Cheng, Riqing, Zhang, Wenyao, Gao, Xin, Wang, Laibing, Qi, Herima, Yu, Shuyan, Chen, Jianping, Ma, Lan, Guo, Huiqing
Format: Article
Language:English
Subjects:
Advertising executives
Alcohol
Anti-inflammatory drugs
Atopic dermatitis
Bioavailability
Castor oil
Cytokines
Dermatitis
Drug dosages
Effectiveness
Ethanol
In vivo methods and tests
Irritation
Methylene blue
microemulsion
microemulsion gel
Microemulsions
Particle size
patchouli oil
Permeability
Polydispersity
preparation process
quality evaluation
Skin
Transdermal medication
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patchouli oil (PO) is a natural substance famous for its immune-enhancing and anti-inflammatory effects. Atopic dermatitis (AD) is characterized by epidermal gene mutations, skin barrier dysfunction, and immune dysregulation, making patchouli volatile oil a potential candidate for AD treatment. Initially, PO was mixed with ethyl oleate (EO), castor oil ethoxylated ether-40 (EL-40), anhydrous ethanol, and water to form a patchouli oil microemulsion (PO-ME) system. The formulation ratios were optimized using the Box-Behnken design-effect surface method, and their products were characterized for type, particle size, polydispersity index (PDI), and appearance. Additionally, patchouli oil microemulsion gel (PO-MEG) was developed with a specified concentration of 1.5% carbomer-940 as the matrix, and its pH, stability, viscosity, and permeability were evaluated. We assessed the irritation tests of PO-MEG using a rat self-control model and the Cell Counting Kit-8 (CCK-8) assay. The results demonstrated that should be attributed to non-irritating. This study also assessed the efficacy of optimized PO-MEG on AD-like symptoms using a 2,4-dinitrochlorobenzene (DNCB)-induced BALB/c mouse model. Compared with the model group, the in vivo efficacy studies have shown the PO-MEG group significantly reduces dermatitis scores, mast cell counts, epidermal thickness, and levels of pro-inflammatory cytokines and immune factors in skin homogenates. This suggests that PO-MEG would become a safer topical formulation for treating atopic dermatitis.
ISSN:2310-2861
2310-2861
DOI:10.3390/gels10120796